SeaPRwire – Page 25 – Today in Hong Kong

SeaPRwire

LINK Business Brokers Brisbane Launches Educational Program for Business Sellers

August 31, 2024

Brisbane, Australia – August 31, 2024 – (SeaPRwire) – LINK Business Brokers Brisbane announces enhancement of educational initiative to empower business sellers with essential knowledge for successful transactions. LINK Business Brokers is amplifying its efforts to educate business sellers by launching an initiative that provides resources and guidance throughout the selling process. This program supports sellers with seminars, personalised consultations, and comprehensive online materials. Co-Director Blair Luckman spoke about LINK’s dedication to education. “Our mission is to empower business sellers by enhancing their understanding of the selling process. This knowledge prepares them for negotiating sales and improves the outcomes of their transactions,” he says. Co-Director Vince Konig adds, “Informed sellers make strategic decisions that positively impact their business deals. Our educational programs are designed to turn sellers into well-informed market participants.” The initiative includes resources like seminars, workshops, and one-on-one consultations to clarify the sales process. LINK experts cover topics such as preparing a business for sale, understanding market valuation, and effective marketing strategies. This approach ensures sellers are well-prepared and confident. LINK also uses advanced technology and data-driven insights to support its educational services. They provide sellers with realistic appraisals, market analyses, and trend reports that aid decision-making. LINK’s educational resources, including webinars, downloadable guides, and an interactive Q&A series where sellers can engage directly with LINK’s expert brokers, are available online. With this initiative, LINK Business Brokers Brisbane continues to lead in the business brokerage industry, supporting their clients through education and empowerment. About LINK Business Brokers Established in 1996, LINK Business Brokers is the largest business brokerage group globally. They operate across New Zealand, Australia, and the USA and are committed to facilitating business sales with confidentiality and integrity. Each broker at LINK is a sector specialist, equipped with deep market knowledge and a commitment to delivering superior service. LINK combines powerful analytics with a personalised approach, establishing itself as a trusted partner in business sales. Contact Information Brand: LINK Business Brokers Brisbane Contact: Media team Email: brisbane@linkbusiness.com.au Website: https://linkbusiness.com.au/business-brokers/brisbane/ The article is provided by a third-party content provider. SeaPRwire ( https://www.seaprwire.com/ ) makes no warranties or representations in connection therewith. Sectors: Top Story, Corporate News SeaPRwire provides real time press release distribution for companies and organizations to 6,500+ media outlets & 3.5 million professional desktops in 90 regions. It distributes press releases in different languages, including: IndonesiaFolk, IndoNewswire, SEATribune, IDNewsZone, LiveBerita, DailyBerita, TaiwanPR, SinchewBusiness, AsiaEase, BuzzHongKong, SingapuraNow, TIHongKong, TaipeiCool, TWZip, AsiaFeatured, dePresseNow, THNewson, KULPR, VNFeatured, MENAEntry, HunaTimes, DubaiLite, ArabicDir, BeritaDaring, TekanAsia, JamKopi ...

SeaPRwire

Dream Draw LLC FZ Expands to European Markets with Unique Shopping Model

August 31, 2024

Dubai, UAE – August 31, 2024 – (SeaPRwire) – Dream Draw LLC FZ, an e-commerce platform known for its creative shopping experience that blends retail with the excitement of raffles, is set to expand its operations into European markets. This move is part of the company’s strategic plan to reach new audiences and further establish its presence in the global e-commerce industry. Dream Draw LLC FZ has seen a strong rise in popularity in the Middle East by offering a diverse range of products from well-known brands. The platform is noted for its straightforward and user-friendly shopping experience, which includes a variety of items such as perfumes and exclusive gifts. Additionally, Dream Draw enhances the shopping experience by offering unique opportunities that add an element of excitement to every purchase, making it a preferred choice for many customers. This model has proven successful, attracting over 100,000 customers and driving significant revenue growth. “We are thrilled to bring Dream Draw to Europe, where we believe our unique blend of shopping and winning will resonate with a wide audience,” said Malik Awan, COO of Dream Draw LLC FZ. “Our expansion into Europe marks a significant milestone for the company and reflects our commitment to offering customers a shopping experience that is both enjoyable and potentially life-changing.” As part of its European expansion, Dream Draw will adapt its platform to cater to regional preferences and regulations, ensuring that customers receive a localized shopping experience. The company is also investing in robust customer support and building strong partnerships with local suppliers and retailers, aiming to offer a wide variety of products that align with European tastes. “We’ve seen tremendous success in the Middle East, and we are confident that our model will thrive in Europe as well,” Awan added. “Our goal is not only to meet but exceed the expectations of our new customers, offering them a seamless and thrilling shopping experience.” About Dream Draw LLC FZ Dream Draw LLC FZ is a creative e-commerce platform based in Dubai, UAE, that combines traditional online shopping with the excitement of a raffle system. Every purchase made on the platform gives customers a chance to win significant prizes, from luxury goods to cash rewards. Founded with the vision of turning ordinary shopping into an extraordinary experience, Dream Draw has rapidly grown its customer base across the Middle East and is now expanding into European markets. For more information, visit www.dreamdraw.us. Contact Information Brand: Dream Draw LLC FZ Contact: Malik Awan Email: customer-support@dreamdraw.us Website: https://dreamdraw.org/ The article is provided by a third-party content provider. SeaPRwire ( https://www.seaprwire.com/ ) makes no warranties or representations in connection therewith. Sectors: Top Story, Corporate News SeaPRwire provides real time press release distribution for companies and organizations to 6,500+ media outlets & 3.5 million professional desktops in 90 regions. It distributes press releases in different languages, including: IndonesiaFolk, IndoNewswire, SEATribune, IDNewsZone, LiveBerita, DailyBerita, TaiwanPR, SinchewBusiness, AsiaEase, BuzzHongKong, SingapuraNow, TIHongKong, TaipeiCool, TWZip, AsiaFeatured, dePresseNow, THNewson, KULPR, VNFeatured, MENAEntry, HunaTimes, DubaiLite, ArabicDir, BeritaDaring, TekanAsia, JamKopi ...

SeaPRwire

GVRenting Unveils Sustainable Solutions in Urban Architecture

August 30, 2024

Green Above: How GVRenting’s Urban Farms Are Shaping a New Future in Ho Chi Minh City Ho Chi Minh, Vietnam – August 30, 2024 – (SeaPRwire) – GVRenting (https://www.gvrenting.com) is proud to announce its sustainable solutions in Urban Architecture, which will Shape a New Future in Ho Chi Minh City. In the teeming urban landscape of Ho Chi Minh City, an innovative agricultural revolution is blossoming where one might least expect it: atop the city’s numerous apartment buildings. Here, amidst the dense metropolitan hustle, GVRenting, a local property management company, is pioneering a radical concept that intertwines the ease of apartment living with the benefits of sustainable farming. Their recent initiative, transforming rooftop spaces into productive hydroponic and aquaponic gardens, is reshaping urban life by offering a slice of agrarian paradise amidst the concrete jungle. Sustainable Foundations in Urban Architecture Established during the housing boom of the early 2010s, GVRenting has grown from a modest property management firm into a visionary leader in urban sustainability. The company oversees a portfolio of properties that range from sleek mid-rise residential complexes to towering high-rises, all of which are now doubling as green agricultural sites. These rooftop farms are not mere aesthetic enhancements. They are fully functional agricultural installations that yield an impressive 3-4 tons of fresh vegetables each month. From lush leafy greens to vibrant herbs and nutritious vegetables, the variety is extensive and all are grown organically. The Roots of Innovation: Hydroponics and Aquaponics At the core of GVRenting’s agricultural success are the sophisticated hydroponic and aquaponic systems that utilize advanced technology to cultivate crops in a controlled, soil-free environment. Hydroponics involves growing plants in a nutrient-rich water solution, a method that significantly reduces water usage compared to traditional soil farming. Aquaponics combines this system with aquaculture (fish farming), where the waste produced by fish supplies nutrients for plants, which in return purify the water for the fish. “This closed-loop system is not only resource-efficient but also provides our tenants with the freshest produce possible,” explains Thae An, head of Agricultural Operations at GVRenting. “Our integrated approach ensures that we maximize space and resources while minimizing waste and environmental impact.” A Harvest of Health and Community One of the most visible impacts of GVRenting’s rooftop farms is their role in enhancing the quality of life for tenants. Residents enjoy unlimited access to fresh, organic vegetables, which are distributed weekly through a community-supported agriculture (CSA) model. “The access to fresh produce right from my building’s rooftop has completely transformed my family’s eating habits,” shares Mai Phuong, a resident and mother of two. “We eat healthier, and my children now understand where their food comes from. They see it grow, and they help harvest it—it’s truly a unique urban living experience.” Moreover, these green spaces serve as communal areas where residents can meet, mingle, and bond over gardening activities. They foster a strong sense of community and connectivity among residents, who take pride in their collective effort to maintain and nurture their urban gardens. Economic and Environmental Impact GVRenting’s initiative also presents significant economic benefits. By reducing dependency on external food sources and minimizing food transport, the company is able to lower its overall carbon footprint. Additionally, the rooftop gardens help insulate the buildings, decreasing the need for artificial cooling and thereby reducing energy costs. The environmental benefits are equally impressive. Urban agriculture helps combat the heat island effect common in metropolitan areas, where buildings and roads trap heat, leading to significantly higher temperatures. The plants on the rooftops absorb sunlight, CO2, and heat, helping to moderate the temperature of the buildings and surrounding areas. Looking to the Future Encouraged by the success of their current projects, GVRenting is planning to expand their green initiatives. Future projects include increasing the diversity of crops grown, integrating solar panels to power farm operations, and potentially opening up the gardens to the local community for educational programs. “As we look to the future, our goal is to not only expand our operations but to also inspire other companies and communities to consider similar sustainable practices,” states Vuong Tri Dung, CEO of GVRenting. “We believe that our model of integrating agriculture into urban living can play a crucial role in addressing food security and sustainability challenges in urban environments around the world.” As cities continue to grow and the pressure on rural agricultural areas intensifies, innovative solutions like GVRenting’s urban farms offer a promising path forward. By transforming underutilized spaces into vibrant hubs of productivity and community, GVRenting is paving the way for a more sustainable and food-secure future. Their projects serve as a beacon of innovation, demonstrating that even in the heart of a bustling city, nature can thrive and nourish. Through their commitment to sustainability, community, and innovation, GVRenting is not just reimagining what urban buildings can encapsulate; they are redefining what it means to live in a city. This blend of urban living and agrarian bounty is more than a novelty—it’s a forward-thinking solution to some of the most pressing issues of our time: food security, sustainability, and community cohesion. As GVRenting continues to cultivate these green spaces, they are planting the seeds for a greener, more sustainable future, proving that even the busiest urban environments can be reengineered to contribute positively to the planet and its people. This ambitious project by GVRenting stands as a vibrant testament to the power of innovation and the potential of urban spaces to foster a healthier, more connected, and sustainable way of life. Media contact Brand: GVRenting Contact: Media team Website: https://www.gvrenting.com SOURCE: GVRenting The article is provided by a third-party content provider. SeaPRwire ( https://www.seaprwire.com/ ) makes no warranties or representations in connection therewith. Sectors: Top Story, Corporate News SeaPRwire provides real time press release distribution for companies and organizations to 6,500+ media outlets & 3.5 million professional desktops in 90 regions. It distributes press releases in different languages, including: IndonesiaFolk, IndoNewswire, SEATribune, IDNewsZone, LiveBerita, DailyBerita, TaiwanPR, SinchewBusiness, AsiaEase, BuzzHongKong, SingapuraNow, TIHongKong, TaipeiCool, TWZip, AsiaFeatured, dePresseNow, THNewson, KULPR, VNFeatured, MENAEntry, HunaTimes, DubaiLite, ArabicDir, BeritaDaring, TekanAsia, JamKopi ...

SeaPRwire

B2BROKER and Spotware Partnership – B2COPY Now Integrated with cTrader

August 29, 2024

New York, NY – August 29, 2024 – (SeaPRwire) – B2BROKER, the company behind the powerful B2COPY investment solution, is pleased to announce its full integration with Spotware’s cTrader, the premium and first Open Trading Platform. This integration offers cTrader brokers and traders the ability to leverage both platforms’ innovative features and enjoy a superior, more efficient copy trading experience. Special Characteristics of B2COPY on cTrader Platform B2COPY introduces an innovative institutional-grade copier for cTrader, the first of its kind that doesn’t require users to log into their cTrader accounts. Additionally, B2COPY is rolling out the first-ever PAMM (Percent Allocation Management Module) for cTrader. The MAM (Multi-Account Manager) solution from B2COPY stands out with its institutional-level services, such as automated fee payment processing, smooth integration with IB modules, and progressive risk management offerings. The Edge of B2COPY cTrader’s integration with B2COPY introduces several upgraded capabilities. Trading Flexibility – Investors using B2COPY on cTrader can manage trades on their accounts, close positions that were copied, and detach their trades from the master’s positions. Flexible Fee Settings – Masters can alter their fee plans, craft promotional deals for clients, and implement different fee structures tailored to individual clients. Multiple Allocation Methods – B2COPY on cTrader provides flexibility with various allocation methods, including equity-based proportional allocation, balance allocation, and fixed lot allocation. Advanced Copying Features – B2COPY on cTrader includes functionalities such as pausing and reversing copy trades, personalising user nicknames and avatars, and changing the names of strategies. User-Friendly Integrations – B2COPY’s seamless integration with B2CORE CRM, along with compatibility with other proprietary CRMs, means users do not need to access the trading platform separately. Website Widgets – The integration widgets provided by B2COPY on cTrader, including leaderboards and personal statistics pages, help enhance user engagement and promote transparency. Why cTrader cTrader is a distinguished multi-asset FX/CFD trading platform, recognised for its powerful and all-encompassing ecosystem, serving the broad needs of Brokers, Prop Firms, IBs, and Traders. cTrader enables seamless integration with third-party services through its multiple APIs. The Open API simplifies the process of developing custom applications that are connected to the cTrader backend. Brokers and prop firms can customise the cTrader UI extensively with plugins, allowing for the incorporation of bespoke features that align with their business needs. Brokers and prop firms receive cTrader as a cloud-based solution, delivered ready-to-use and hosted on Spotware’s top-tier infrastructure, ensuring exceptional performance. cBroker, included in the cTrader suite, is a flexible and powerful management system that provides brokers and prop firms with endless possibilities for system customisation and management. Brokers and prop firms can confidently build a competitive edge and enhance their market reputation with cTrader, the fastest-growing FX/CFD trading platform. Within the trading community, cTrader is celebrated for its impressive features, including: Diverse order types coupled with advanced protection features Extensive charting tools and technical analysis options Level II market data with rapid execution speeds Smooth entry into algorithmic and social trading Visually appealing UI with a user-focused design Support across all major platforms: web, desktop, macOS, iOS and Android. IBs consider cTrader the top choice for expanding their referral base with: cTrader Invite – A complete toolkit designed to aid partners in attracting new traders by showcasing appealing cTrader products and converting them into referrals effectively. cTrader Copy – A full-scale social trading platform with hundreds of successful strategies, crafted to engage new users and foster live trading participation. cTrader Algo – A sophisticated automated trading solution that simplifies algorithm creation and supports 24/7 cloud execution of cBots on all cTrader apps. Additional partner tools – Features include signal links for sharing trading opportunities, Chart Streams for distributing technical analysis, and shared access for money managers, among other benefits. “With this integration with Spotware, we have brought advanced features and unprecedented flexibility to the traders. B2COPY offers the first-ever PAMM and MAM for professional money managers, multiple allocation methods, and a variety of fee types, including subscription and joining fees, to cTrader users. Also, our performance fee calculation options provide more flexibility for brokers and their clients. We’ve worked really hard to integrate these sophisticated features into B2COPY, and we’re excited to welcome cTrader and their users to experience these benefits.” by Sergey Ryzhavin, CPO of B2COPY “We are excited that B2BROKER has joined our extensive network of partners, and thrilled to develop the market together. At cTrader, we are committed to collaborating with top technology providers to deliver an exceptional and premium trading experience to our users. Through partnerships like this, cTrader maintains its status as the first Open Trading Platform, offering limitless opportunities for integration and customisation within our platform.” by Ilia Iarovitcyn, CEO of Spotware (Creators of cTrader) B2BROKER and Spotware believe that their partnership will advance the trading community, improve user experience and operational efficiency, and serve as a significant step forward for both prominent solution providers. About Spotware Spotware is a global technology provider, successfully delivering cutting-edge fintech solutions and infrastructure for over 14 years. The company has cultivated a sophisticated network of 250+ brokers and prop firms, including notable names like IC Markets, Pepperstone, FTMO, and Funding Pips. With a user base exceeding 4 million traders, cTrader, Spotware’s flagship platform, stands out for its unparalleled innovativeness and user-friendly UI, setting new standards across the industry. For more details or to request a demo, please reach out. B2BROKER – sales@b2broker.com Spotware – sales@spotware.com Media contact Brand: B2Broker Contact: +44 208 068 8636 Contact: Ketevan Julukhadze E-mail: sales@b2broker.com Website: https://b2broker.com The article is provided by a third-party content provider. SeaPRwire ( https://www.seaprwire.com/ ) makes no warranties or representations in connection therewith. Sectors: Top Story, Corporate News SeaPRwire provides real time press release distribution for companies and organizations to 6,500+ media outlets & 3.5 million professional desktops in 90 regions. It distributes press releases in different languages, including: IndonesiaFolk, IndoNewswire, SEATribune, IDNewsZone, LiveBerita, DailyBerita, TaiwanPR, SinchewBusiness, AsiaEase, BuzzHongKong, SingapuraNow, TIHongKong, TaipeiCool, TWZip, AsiaFeatured, dePresseNow, THNewson, KULPR, VNFeatured, MENAEntry, HunaTimes, DubaiLite, ArabicDir, BeritaDaring, TekanAsia, JamKopi ...

SeaPRwire

maXwin, the Leading Online Gaming Platform Breaks into the Asian Market

August 29, 2024

Asia’s Only Online Gaming Platform without Withdrawal Limits Kuala Lumpur, Malaysia – August 29, 2024 – (SeaPRwire) – With the continuous development of the online gaming market, maXwin has successfully entered the Asian market, aiming to elevate online gaming to a whole new level with its unique advantages and exceptional services. As the only online gaming platform in Asia without withdrawal limits, maXwin quickly stands out in the market, attracting a large number of players with its innovative operating model and steadfast commitment. Mr. Harry Willson, Founder and CEO of maXwin, stated, “We are dedicated to providing players with a free, safe, and worry-free online gaming platform. Our goal is to break the traditional restrictions of online gaming platforms, allowing players to withdraw their winnings freely anytime and anywhere, enjoying an unparalleled gaming experience.” Unmatched Freedom and Convenience As an industry innovator, maXwin’s promise of “no limits on profit withdrawals” has completely revolutionized the traditional limitations imposed by online gaming platforms on player withdrawals. This groundbreaking initiative allows players to enjoy the fun of gaming without worrying about withdrawal issues, truly achieving the freedom to “withdraw whenever you want.” Legal and Secure Assurance maXwin holds the internationally recognized Curacao gaming license, ensuring the platform’s legality and security. Players can confidently game on maXwin, enjoying top-notch security and privacy protection. Mr. Harry Willson emphasized, “We highly value the security and privacy of our players, ensuring that every player can enjoy games in a safe and fair environment.” A Rich Variety of Game Choices maXwin offers more than hundreds of different types of games, including popular slots, exciting live dealer games, thrilling sports betting, and captivating e-sports. Whether you are a beginner or an experienced player, you will find your favorite games here. To welcome new players, maXwin has launched an astonishing 300% bonus, allowing players to enjoy generous rewards as they embark on their gaming journey. Award-Winning Excellence In the 2023 Sigma Awards, maXwin was named the Best Online Gaming Platform. This honor not only affirms maXwin’s exceptional gaming experience but also recognizes its continuous innovation and high-quality services. Mr. Harry Willson remarked, “We will continue to strive to improve our service levels, ensuring that every player enjoys the best gaming experience at maXwin.” Mission and Vision: Leading the Industry to New Heights maXwin’s mission and vision are to address the current market issues of security and gaming experience, striving to provide a safer and more premium gaming platform for players. We not only focus on the entertainment experience but also aim to take online gaming to new heights, creating a new era in gaming. Mr. Harry Willson concluded, “Our goal is to ensure that every player finds joy and satisfaction at maXwin. We believe that through continuous innovation and service optimization, maXwin will become the preferred online gaming platform for players in Asia and around the world.” With maXwin successfully breaking into the Asian market, this passionate and innovative community will bring unprecedented gaming freedom and fun to more players. Whether you seek thrilling gaming experiences or hope to earn substantial rewards, maXwin is the best choice for players. Challenge the limits, Beyond Limit—only at maXwin. Social Links Facebook: https://www.facebook.com/profile.php?id=61564638481329 Instagram: https://www.instagram.com/maxwin.my/ TikTok: https://www.tiktok.com/@maxwin_official88 Youtube: https://www.youtube.com/@maXwinofficial-88 Media contact Brand: maXwin Contact: Media team Email: support@maxwinofficial.com Website: https://maxwinofficial.com/ The article is provided by a third-party content provider. SeaPRwire ( https://www.seaprwire.com/ ) makes no warranties or representations in connection therewith. Sectors: Top Story, Corporate News SeaPRwire provides real time press release distribution for companies and organizations to 6,500+ media outlets & 3.5 million professional desktops in 90 regions. It distributes press releases in different languages, including: IndonesiaFolk, IndoNewswire, SEATribune, IDNewsZone, LiveBerita, DailyBerita, TaiwanPR, SinchewBusiness, AsiaEase, BuzzHongKong, SingapuraNow, TIHongKong, TaipeiCool, TWZip, AsiaFeatured, dePresseNow, THNewson, KULPR, VNFeatured, MENAEntry, HunaTimes, DubaiLite, ArabicDir, BeritaDaring, TekanAsia, JamKopi ...

SeaPRwire

守護健康與愛，醴厚生醫：將”利他”精神融入每一款產品

August 27, 2024

Singapore - 2024年8月27日 - (SeaPRwire) - 醴厚生醫自成立以來，始終秉持著「利他」精神，致力於通過高品質的健康產品，喚醒人們對自身健康的關注，並將這份關愛延伸到身邊每一個人。發言人陳欣佑在接受《The Icons》艾肯氏國際名人誌採訪時表示：「『利他』不能只是口號，而應該從心底深處去相信，並且義無反顧地實踐。創辦人希望通過醴厚生醫的品牌精神，喚醒現代人，尤其是女性，真正地去愛自己，只有這樣，才能在家庭與事業中找到平衡，也才能真正地愛別人。」她堅信，將「利他」昇華為「永續利他」，不僅是企業發展的核心，更是對社會與環境的最大貢獻。 [caption id="attachment_2350" align="aligncenter" width="800"] 醴厚生醫發言人陳欣佑[/caption] 醴厚生醫專注於天然健康產品的研發與生產，其明星產品之一「愛妳膠原蛋白」，以天然的魚膠原蛋白為主，搭配維生素C，能有效促進肌膚的彈性和光澤，深受現代女性的喜愛。這款產品不僅成分安全無添加，更符合健康與環保的雙重要求，讓消費者能安心使用。此外，醴厚生醫還推出了「有機油甘一口雲」，這款產品選用了被印度⼈稱之為「⽣命之果」的嘉寶果作為原料，從外⽪、果⾁到種籽含有豐富營養素，如花青素、菸鹼酸、礦物質等。有助於抗氧化、促進膠原蛋⽩形成。有機油甘一口雲不僅適合一般消費者，更是經常外食、生活壓力大的現代人的理想選擇。陳欣佑提到，醴厚生醫的產品開發過程中，特別注重原材料的選擇和製程的環保性。「我們希望每一款產品都能成為消費者健康生活的守護者，同時也不忘保護我們賴以生存的環境。」她表示，醴厚生醫不僅是要為消費者提供健康產品，更要通過這些產品傳遞一份對於健康和環境的關懷。然而，企業的成功之路並非一帆風順。疫情的爆發讓全球經濟陷入停滯，醴厚生醫的擴展計劃也被迫中斷。但在面對挑戰時，創辦人選擇了反思和重整，她重新確立了以永續發展為導向的企業路線。這一決策不僅幫助醴厚生醫渡過難關，也讓企業在市場上更具競爭力。在此過程中，醴厚生醫特別關注女性群體的需求。創辦人認為，許多女性在家庭與事業間難以找到平衡，往往為了家庭而忽視了自己的健康。她希望通過醴厚生醫的產品，幫助女性找回自我價值，並在社會中發揮更大的影響力。隨著企業的發展，醴厚生醫的影響力逐漸擴展至國際市場，尤其是在新加坡等東南亞國家。創辦人表示，希望更多女性能通過醴厚生醫的產品，重新找回自我，並用健康的身心去面對生活的挑戰。她強調，「真正的愛人，勢必建立在先愛自己的基礎上，而這也是醴厚生醫始終堅持的品牌信念。」 Media contact Brand: Hou Gift Biosciences Contact: support team Email: contact@hougiftbio.com Website: https://www.hougiftbio.com/ SOURCE: Hou Gift Biosciences

SeaPRwire

MVL Launches TADA mini Beta: Ride-Hailing Available via Telegram

August 23, 2024

Seoul, Korea – August 23, 2024 – (SeaPRwire) – MVL, led by CEO Kay Woo, has announced the beta launch of TADA mini, an innovative ride-hailing service that leverages Telegram bots. While the official launch is scheduled for early September, MVL is hosting a special airdrop event to celebrate this launch. TADA mini is the first real-world utility service for the Web3 world, allowing users to book rides directly through Telegram without the need for additional apps or complicated authentication processes. In addition to ride-hailing, the TADA mini app offers a wide array of features, including multiple vehicle options, live driver tracking, and trip-sharing capabilities. By linking TADA’s network of nearly 300,000 drivers with Telegram’s 900 million users, TADA mini enables seamless real-time communication. Users of the TON blockchain can even request rides through their Tonkeeper wallets, with refunds processed directly to their blockchain wallet in case of cancellations or issues. Currently, TADA mini is in the final stages of testing and will be officially launched to all users in Singapore in early September. The service will also play a key role in providing on-site transportation for Token 2049, the world’s leading cryptocurrency event, taking place in the third week of September. In celebration of TADA mini’s launch, MVL is hosting a referral event for Web3 users, offering 50 million MVL tokens as rewards. Participants can earn mission points by engaging with chatbots, following social media channels, and inviting friends. These points will later be airdropped as MVL tokens after the event concludes. TADA Mini offers real-time ride-hailing and mission features, all easily accessible through this link: https://t.me/TADA_Ride_Bot . MVL’s representative stated, “TADA mini is set to become a significant player in the industry by enhancing the usability of ride-sharing services through integration with Web3 projects. Following the initial launch in Singapore, we plan to expand the service to Cambodia, Vietnam, Thailand, and other countries.” About MVL MVL is committed to driving innovation in the mobility sector through blockchain technology. The company operates real-world mobility services across Asia, including TADA, the second-largest ride-sharing platform in Southeast Asia, and ONiON Mobility, a brand focused on electric vehicles and infrastructure. Building on these services, MVL is developing projects like MVL-Fi, which focuses on sharing mobility value, and DePIN, which is centered on data sharing. Social Links Facebook: https://www.facebook.com/mvlchain X: https://twitter.com/mvlchain YouTube: https://www.youtube.com/channel/UCWIwx5KcQIaf7Ti6piFhnKw LinkedIn: https://www.linkedin.com/company/mvlchain/ Media Contact Brand: MVL Contact: Rose Purevdorj E-mail: mvlsupport@mvlchain.io Website: https://mvlchain.io SOURCE: MVL The article is provided by a third-party content provider. SeaPRwire ( https://www.seaprwire.com/ ) makes no warranties or representations in connection therewith. Sectors: Top Story, Corporate News SeaPRwire provides real time press release distribution for companies and organizations to 6,500+ media outlets & 3.5 million professional desktops in 90 regions. It distributes press releases in different languages, including: IndonesiaFolk, IndoNewswire, SEATribune, IDNewsZone, LiveBerita, DailyBerita, TaiwanPR, SinchewBusiness, AsiaEase, BuzzHongKong, SingapuraNow, TIHongKong, TaipeiCool, TWZip, AsiaFeatured, dePresseNow, THNewson, KULPR, VNFeatured, MENAEntry, HunaTimes, DubaiLite, ArabicDir, BeritaDaring, TekanAsia, JamKopi ...

SeaPRwire

Next-Level AML: XBO.com Integrates Elliptic’s Compliance Solution

August 20, 2024

Compliance being a pressing issue, crypto players like XBO.com seek partnerships with top AML solution providers New York, NY – August 20, 2024 – (SeaPRwire) – In the rapidly evolving cryptocurrency landscape, platforms like XBO.com, a leading B2C crypto service, are at the forefront of ensuring secure and compliant trading environments. As the crypto market matures, the “Wild West” days of unregulated financial flows are giving way to a new era where compliance and transparency are paramount. XBO.com is setting the standard by integrating cutting-edge Anti-Money Laundering (AML) solutions to protect its users and foster trust in the digital finance ecosystem. XBO.com recognizes the importance of regulatory compliance in today’s crypto market. To maintain its position as a trusted crypto service, XBO.com has adopted robust AML measures that not only ensure legal operations but also build confidence among users and investors, especially those new to the world of digital currencies. AML and Compliance: Cornerstones of XBO.com’s Strategy As a comprehensive crypto service, XBO.com understands that adherence to AML regulations is essential for the long-term success of any crypto platform. Compliance helps prevent illegal activities such as money laundering, which can undermine the credibility of the entire financial ecosystem. XBO.com is committed to upholding the highest standards of legal compliance, which is crucial for maintaining its reputation as a trustworthy platform in the eyes of both regulators and users. For crypto exchanges like XBO.com, implementing strong AML policies is not just about meeting regulatory requirements—it’s about safeguarding the entire crypto market from exploitation by bad actors. By ensuring full compliance with global and local regulations, XBO.com reinforces its commitment to transparency and user protection, making it a go-to platform for both seasoned and novice crypto enthusiasts. XBO.com: A Model of Compliance and User-Centric Innovation While many crypto platforms strive to meet legal requirements, XBO.com goes above and beyond by actively seeking out partnerships with industry leaders in compliance technology. This proactive approach ensures that XBO.com remains at the cutting edge of security and user protection. Emerging as a leader in the crypto exchange sector, XBO.com offers a user-friendly and innovative platform that has evolved into a full-fledged crypto ecosystem. XBO.com is not just a trading platform; it is a comprehensive service where users can access a wide range of features, from spot trading to earning interest on digital assets. The platform’s intuitive design and commitment to accessibility are encapsulated in its motto: “Crypto. Made for everyone.” This philosophy, combined with rigorous compliance measures, sets XBO.com apart in a highly competitive market. Elevating AML Standards: XBO.com Partners with Elliptic In its quest to achieve the highest standards of compliance, XBO.com has partnered with Elliptic, a globally recognized leader in AML and compliance technology for the crypto industry. This strategic alliance highlights XBO.com’s unwavering dedication to lawfulness and user safety. By leveraging Elliptic’s advanced blockchain analytics, XBO.com can detect and prevent illicit activities, ensuring that all transactions on the platform are secure and compliant with global standards. Elliptic provides a comprehensive suite of services that enhance XBO.com’s ability to monitor transactions and identify potential risks. From Wallet Screening and Transaction Monitoring to Crypto Investigations, Elliptic’s tools empower XBO.com to maintain the highest levels of compliance and user protection. This partnership not only strengthens XBO.com’s security infrastructure but also positions the platform as a leader in the fight against money laundering and other financial crimes. Maximizing User Benefits Through Strategic Partnerships By integrating Elliptic’s state-of-the-art AML solutions, XBO.com offers its users an unparalleled level of security and compliance from the moment they join the platform. This collaboration allows XBO.com to implement cutting-edge tools without the delays associated with developing an in-house system, ensuring that users benefit from the highest standards of protection and trust. XBO.com’s decision to partner with an industry leader like Elliptic underscores its commitment to providing a secure and compliant trading environment. This move not only enhances user trust but also solidifies XBO.com’s reputation as a responsible and forward-thinking crypto service. Building Trust and Transparency in the Crypto Industry As the cryptocurrency industry continues to evolve, partnerships like the one between XBO.com and Elliptic are essential for advancing regulatory standards and building trust among users and the broader public. XBO.com is leading by example, showing that a commitment to compliance and transparency is key to the future success of the crypto market. By prioritizing legal standards and integrating the best available technologies, XBO.com is setting a benchmark for other crypto platforms to follow. This dedication to legality and transparency will contribute to a safer and more reliable future for all users in the cryptocurrency space. As the industry matures, XBO.com’s partnership with Elliptic will play a crucial role in ensuring that the platform remains a trusted and secure environment for all its users, ultimately helping to shape the future of digital finance. Media Contact Brand: XBO Contact: Media team Website: https://www.xbo.com SOURCE: XBO The article is provided by a third-party content provider. SeaPRwire ( https://www.seaprwire.com/ ) makes no warranties or representations in connection therewith. Sectors: Top Story, Corporate News SeaPRwire provides real time press release distribution for companies and organizations to 6,500+ media outlets & 3.5 million professional desktops in 90 regions. It distributes press releases in different languages, including: IndonesiaFolk, IndoNewswire, SEATribune, IDNewsZone, LiveBerita, DailyBerita, TaiwanPR, SinchewBusiness, AsiaEase, BuzzHongKong, SingapuraNow, TIHongKong, TaipeiCool, TWZip, AsiaFeatured, dePresseNow, THNewson, KULPR, VNFeatured, MENAEntry, HunaTimes, DubaiLite, ArabicDir, BeritaDaring, TekanAsia, JamKopi ...

China Medical System (00867) Released its 2024 Interim Results:Steady Increase in Revenue and Profit Compared with 2H 2023

August 16, 2024

CMS enters the “New Product Era” driven by exclusive and innovative products, with exclusive and innovative drugs revenue accounts for over 56%. SHENZHEN, CHINA – August 15, 2024 – (SeaPRwire) – On August 15, 2024, China Medical System Holdings Limited (“CMS” or the “Company”) released its 2024 interim results announcement, with a steady increase in overall revenue and profit for the period compared to the second half (2H) of 2023. In the first half (1H) of 2024, the Company recorded a turnover of RMB3,611.1 million, representing a decrease of 21.7% compared with 1H 2023, an increase of 6.1% compared with 2H 2023. In the case that all medicines were directly sold by the Company, the turnover was RMB4,287.5 million, representing a decrease of 22.6% compared with 1H 2023, an increase of 8.9% compared with 2H 2023; Among which, the total revenue of non-National VBP exclusive products and innovative products was RMB2,404.7 million, accounting for 56.1% of CMS’s revenue in the case that all medicines were directly sold by the Company. Profit for the period was RMB903.4 million, representing a decrease of 52.8% compared with 1H 2023, a substantial increase of 92.8% compared with 2H 2023. The year 2024, not only marks the first year of the commercialization of CMS’s innovative products, but also a crucial point for the release of National Volume Based Procurement (“National VBP”) impact on its financial performance. Deanxit entered the seventh batch of National VBP in November 2022, Plendil and Ursofalk entered the eighth batch of National VBP in July 2023, and none of the three original drugs were selected, which had a negative impact on the Company’s business performance. In 1H 2024, the Company’s overall performance showed a growth trend compared with 2H 2023, indicating that CMS has basically digested the impact of National VBP and successfully entered the “New Product Era” where non-national VBP exclusive products and innovative products drive its growth. With the approval for marketing of LUMEBLUE (Methylthioninium Chloride Enteric-coated Sustained-release Tablets) in June and METOJECT (Methotrexate Injection)’s additional indication of active rheumatoid arthritis (RA) in adults in July this year, CMS’s innovative drug portfolio in the commercialization stage has expanded into 5 products (including 6 indications); simultaneously with a rich and differentiated innovative pipeline reserve. Gathering the power of innovation and riding the momentum of development, CMS is comprehensively shaping new drivers for development with a healthier product structure, further opening up a new cycle of quality development. The “Collaborative and In-house” dual-engine R&D model drives the simultaneous improvement in quantity and quality of the pipeline, accelerating the transformation of innovative biotechnology A profound innovative drug R&D pipeline is an important driving force for the long-term development of CMS. The Company adheres to the purpose of innovation for meeting the unmet clinical needs and solving the difficulties of patient medication, and promotes innovation development through a two-wheel drive of “Collaborative R&D and In-house R&D”, continuously deploying FIC (first-in-class) and BIC (best-in-class) innovative products, and enhancing the capabilities and efficiency of research and clinical development to achieve a rapid transformation of scientific outcomes into social and commercial values. As of now, CMS’s innovative product portfolio approved for marketing in China has been expanded into 5 products (including 6 indications), among which, 4 innovative drugs (VALTOCO, ILUMETRI, METOJECT – psoriasis indication, VELPHORO) have been included in the National Reimbursement Drug List (NRDL) and entered large-scale clinical application; also, CMS newly added LUMEBLUE and METOJECT (RA), for being approved for marketing in China recently. CMS has also steadily advanced the clinical development of innovative products. Currently, Desidustat Tablets is under NDA review in China; Also, a total of about 10 projects have been prepared/launched for their registrational clinical trials, mainly randomized controlled trials (RCT). At the same time, the Company had continued to strengthen basic research and independent innovation capabilities, and successfully promoted more than 10 in-house R&D projects, among which, three innovative drugs (VEGFA/ANG2 Tetravalent Bispecific Antibody, Highly Selective TYK2 Inhibitor CMS-D001 Tablets, and GnRH Receptor Antagonist CMS-D002 Capsules) have entered the clinical development stage. In addition, the Company’s innovative pipeline has continued to expand. CMS Skinhealth collaborated with Incyte once again, and has obtained exclusive license to research, develop, register and commercialize povorcitinib, a selective oral small-molecule JAK1 inhibitor, in countries/territories including Mainland China, Hong Kong, Macau, Taiwan Region and 11 Southeast Asian countries. This further enriched the product portfolio of CMS Skinhealth in the treatment of vitiligo and other immune-mediated dermatology diseases. Subsequently, CMS will continue to produce innovative products with higher efficiency and more controllable costs every year, accelerating the release of innovative value and embracing quality and sustainable performance growth through a healthy product structure dominated by non-National VBP exclusive products and innovative products. Successful commercialization system releases the clinical value of innovative products in an efficient and collaborative manner After 32 years of deep cultivation in specialty therapeutical fields, successful commercialization capability is one of CMS’s core competitiveness. By continuously reinforcing and integrating its commercialization platform, it has achieved in-depth development of its three major business segments including cardio-cerebrovascular/gastroenterology, dermatology, and ophthalmology, and expanded its boundaries in related fields. Additionally, the Company established a highly qualified, professional promotion team with strong execution, as well as extensive channel and resource coverage, which has laid a solid foundation for the rapid market entry and brand building of its innovative products. Four innovative drugs of CMS have entered large-scale clinical applications, covering various disease fields such as central nervous system, dermatology, nephrology, and gastroenterology, and developed synergistically with the existing marketed products in promotion team and channels. Meanwhile, leveraging on the opportunity of being included in the NRDL, CMS is advancing hospital development, brand building, real world studies and medically-driven academic promotion. CMS is improving patients’ accessibility to innovative drugs with the help of patient aid and disease knowledge popularization programs, promoting the release of products’ clinical value. The Dermatology and Medical Aesthetic Business “CMS Skinhealth” regards dermatology prescription products as its core, and extends to light medical aesthetic products and dermatology-grade skincare products, continuously improving the construction of a full life-cycle skin-health management platform covering dermatological treatment, skincare, and medical aesthetics through internal development and external collaboration. In terms of clinical development of dermatology prescription drugs, CMS has completed the Pivotal Real World Study for ruxolibinib cream in vitiligo, and is advancing the registration application process in Mainland China. At the same time, it has continuously complemented the regenerative light medical aesthetic portfolio, among which the China’s medical device registration application of the Poly-L-lactic Acid Microparticle Filler Injection has been accepted by the NMPA during the Reporting Period; and the Company has newly obtained exclusive licenses of three regenerative light medical aesthetic products (Polycaprolactone Microsphere Gel for injection, Calcium Hydroxylapatite Microsphere Gel for injection, and Decellularized Extracellular Matrix Implant), which are currently under the registrational clinical trial stage in China. The results announcement shows that, as of the end of June, the promotion network of CMS has covered over 55,000 hospitals and medical institutions, and approximately 280 thousand retail pharmacies in China. Leveraging the accumulated advantages in cardio-cerebrovascular, gastroenterology, central nervous system, nephrology, ophthalmology, dermatology and other specialty therapeutical fields, CMS steadily releases the scale effect of its specialty businesses, and builds high competition barriers, creating broad commercial potential for its innovative products and exclusive products. Drawing up the internationalization layout to gather momentum for the incremental market Integrating the advantageous resources of the Company, its Southeast Asia business “Rxilient Health”, shares and expands the successful experience of CMS gained from the China market, as well as global quality products and innovative technological resources, into the Southeast Asia market. This accelerates the improvement of the platform integrating “R&D, manufacture, and commercialization” of the Southeast Asia business, empowering Chinese and global pharmaceutical companies to implement the “overseas development” strategy, and also opening up a larger space for incremental development opportunities for CMS. As of the end of June, Rxilient Health has established a competitive product portfolio with more than ten differentiated products, covering therapeutic areas such as oncology, central nervous system, autoimmune, dermatology, and ophthalmology, etc. Rxilient Health is accelerating the relevant work on the market registration processes in Southeast Asian countries for innovative pipeline products, such as ruxolitinib cream, Methylthioninium Chloride Enteric-coated Sustained-release Tablets, and Diazepam Nasal Spray, etc. Furthermore, Rxilient Health collaborated with Junshi Biosciences to promote the registration process of toripalimab (anti-PD-1 monoclonal antibody) in multiple countries in Southeast Asia, aiming to benefit local cancer patients as soon as possible. In December last year, the Company and Rxilient Health joined hands with Pharmaron and other partners to complete the purchase of the Singapore manufacturing plant. This year, all relevant parties have been orderly advancing a series of work for the Singapore manufacturing plant, including equipment testing, quality verification, and production quality system certification, etc., so as to accelerate the CDMO business development, and to optimize the Company’s overseas supply chain and manufacturing capabilities. The business layout will further facilitate more inter-industry cooperation between CMS and global partners in the future, thus jointly building a win-win medical innovation ecosystem with mutual benefits. Conclusion Since its establishment in 1992, CMS has followed the development pattern of the industry and has promoted three significant strategic transformations successfully with a forward-looking vision. The Company started as an agent of imported original drugs, gradually developed to control the rights of original/exclusive products, and then achieved a comprehensive innovative transformation. Each step of the transformation is in sync with the industry development trends. CMS steadily aims towards the ultimate goal, and constantly builds up its strength and resilience to persist through the industry development cycle. With the gradual release of the impact of national VBP on its financial performance, CMS has been transforming into a brand-new company. While embracing the innovation achievements in each stage, CMS is fully prepared for a sustainable and healthier development in the future. About CMS CMS is a platform company linking pharmaceutical innovation and commercialization with strong product lifecycle management capability, dedicated to providing competitive products and services to meet unmet medical needs. CMS focuses on the global first-in-class (FIC) and best-in-class (BIC) innovative products, and efficiently promotes the clinical research, development and commercialization of innovative products, enabling the continuous transformation of scientific research into clinical practices to benefit patients. CMS deeply engages in several specialty therapeutic fields, and has developed proven commercialization capabilities, extensive networks and expert resources, resulting in leading academic and market positions for its major marketed products. CMS continues to promote the in-depth development of its advantageous specialty fields and expand business boundaries. While strengthening the competitiveness of the cardio-cerebrovascular/gastroenterology business, CMS independently operates its dermatology and medical aesthetics business, and ophthalmology business, aiming to gain leading positions in specialty therapeutic fields, whilst enhancing the scale and efficiency. At the same time, CMS has expanded its business territory to the Southeast Asian market, striving to become a “bridgehead” for global pharmaceutical companies to enter the Southeast Asian market, further escorting the sustainable and healthy development of the Group. CMS Disclaimer and Forward-Looking Statements This press release is not intended to promote any products to you and is not for advertising purposes. This press release does not recommend any drugs, medical devices and/or indications. If you want to know more about the diagnosis and treatment of specific diseases, please follow the opinions or guidance of your doctor or other medical and health professionals. Any treatment-related decisions made by healthcare professionals should be based on the patient’s specific circumstances and in accordance with the drug package insert. This press release which has been prepared by CMS does not constitute any offer or invitation to purchase or subscribe for any securities, and shall not form the basis for or be relied on in connection with any contract or binding commitment whatsoever. This press release has been prepared by CMS based on information and data which it considers reliable, but CMS makes no representation or warranty, express or implied, whatsoever, and no reliance shall be placed on, the truth, accuracy, completeness, fairness and reasonableness of the contents of this press release. Certain matters discussed in this press release may contain statements regarding the Group’s market opportunity and business prospects that are individually and collectively forward-looking statements. Such forward-looking statements are not guarantees of future performance and are subject to known and unknown risks, uncertainties and assumptions that are difficult to predict. Any forward-looking statements and projections made by third parties included in this press release are not adopted by the Group and the Company is not responsible for such third-party statements and projections. Media Contact Brand: China Medical System Holdings Ltd. Contact: CMS Investor Relations Email: ir@cms.net.cn Website: https://web.cms.net.cn/en/home/ Source: China Medical System Holdings Ltd.

SeaPRwire

An Asian Company Achieves Breakthrough in the Key Technology of Ac-225 Preparation

August 15, 2024

PanMediso Holdings’ international team completes core technology verification for mass production of Ac-225 London, UK – August 15, 2024 – (SeaPRwire) -PanMediso Holdings (Shenzhen) Limited, with the collaborative efforts of its international team and under the witness of authoritative experts, has announced a breakthrough in the key production technology for the medical isotope Ac-225 at a conference held in August, 2024,in London, UK. This core technology has been rigorously validated by a well-known research university in the UK, marking a significant milestone for PanMediso in the scale-up and commercial production of Ac-225. (Key members of the PanMediso Holdings’ international team at the Royal Academy of Engineering) PanMediso is a leading global enterprise in the research, production, and sale of medical isotopes Ac-225 and Ge-68. The company’s first phase focuses on addressing the technological and capacity bottlenecks associated with the long-term reliance on imported medical isotopes in China, aiming for realizing the full process flow of Ac-225 and Ge-68 in China. (PanMediso Holdings’ team meeting on the Technology Validation result) The company’s team comprises top experts in nuclear medicine from various countries, including fellows from the Royal Academy of Engineering and the Royal Society of London, a nuclear fuel expert from the UK government, the former chief scientist from a Canadian nuclear laboratory, and authoritative experts and professors from institutions such as Tsinghua University, Imperial College London, Hong Kong Polytechnic University, Shenzhen University, and Southwest Medical University. They are dedicated to research and clinical applications of radioactive isotopes and nuclear medicine. (PanMediso Holdings Team from left to right:Academician Robin Grimes, Chair of the Joint Technical Committee, Academician Andrew Carlick，CEO UK side, Mr. Leo Dang, CEO China side, Mr. Ivan Fu, Chairman of the Board of Directors) Ac-225 is considered one of the most promising therapeutic isotopes in clinical applications. Currently, dozens of Ac-225 drug pipelines are in clinical research stages worldwide, aiming for the treatment of various cancers including prostate cancer, neuroendocrine tumors, non-small cell lung cancer, breast cancer, and multiple solid tumors. Ac-225 has demonstrated excellent therapeutic effects in clinical research and treatment applications. It not only improves patient survival rates and treatment efficacy while reducing side effects but also lowers medical costs. As one of the most promising and highly anticipated medical isotopes, it is in high demand globally. However, only a few advanced teams outside China master the key production technologies for Ac-225, which involves a complex series of nuclear reactions and separation processes, resulting in a highly limited supply and severe long-term resource shortages. The increasing clinical research and treatment needs both domestically and internationally have exacerbated the shortage. PanMediso’s efforts to bridge this significant supply gap have garnered global attention and will effectively support further exploration of new cancer treatments. This dual value underscores PanMediso Holding’s great commitment to advancing global health through technological innovation and international collaboration, with a steadfast goal of contributing to the community with a shared future of mankind. Academician Andrew Carlick, Co-Founder of PanMediso Holdings, snd Director & CEO on UK side, stated, “The cyclotron-based Ac-225 technology employed by PanMediso Holding is highly mature and has been validated by institutions. As the result of our years of wisdom and resources, it features the advantages such as high purity, high yield, low radiation, and minimal raw material loss, and will play a significant role in cancer treatment. With the combined efforts of our international team, we will continue to advance nuclear medicine technology.” Mr. Leo Dang, Co-Founder of PanMediso Holdings, snd Director & CEO on China side, commented, “PanMediso Holdings will continue to focus on technological and process innovations and plans to further expand the application fields of medical isotopes such as Ac-225 and Ge-68. We aim to provide a comprehensive solution from raw materials to finished products, from research to scaling, and to commercial-level production. We are building a complete technological platform for nuclear medicine, covering isotope production, core equipment research and development, nuclear drug RXO, next-gen diagnostic devices and AI+TAT. While intensifing our research and development strength for radiopharmaceuticals, we keep advancing the clinical translation and application of world-leading technologies, contributing PanMediso Holdings Power to scientific research and healthcare.” Contact Us Company: PanMediso Holdings (Shenzhen) Limited Contact: Claire Zhao Email: pchl@panmedisoholdings.com Website: http://panmedisoholdings.com

SeaPRwire

亞洲公司突破Ac-225製備關鍵技術

August 15, 2024

磐美迪國際團隊共同努力，完成Ac-225量產核心技術工藝驗證倫敦- 2024年8月15日 - (SeaPRwire) - 2024年8月，磐美迪控股(深圳)有限公司在國際團隊共同的努力和權威專家的見證下，於英國倫敦發佈突破新型醫用同位素Ac-225關鍵性生產技術的消息，該技術同時得到了英國知名研究型大學的嚴格驗證，為磐美迪在Ac-225的規模商業化量產方面又邁進了具有里程碑意義的一步。 [caption id="attachment_2303" align="aligncenter" width="830"] （磐美迪國際團隊核心成員在英國皇家工程院合影）[/caption] 磐美迪作為國際領先的醫用同位素Ac-225 及Ge-68的研發、生產及銷售企業，首階段致力於解決我國醫用同位素長期依賴進口所面臨的技術和產能瓶頸等“卡脖子”問題，實現Ac-225 及Ge-68 全流程國產化。 [caption id="attachment_2304" align="aligncenter" width="1269"] （磐美迪團隊溝通核心技術驗證結果）[/caption] 公司團隊匯集了多國核醫藥領域的頂尖技術人才，分別由英國皇家工程院和英國皇家科學院的雙院士、英國政府的核燃料專家、加拿大核實驗室的前首席科學家，以及清華大學、英國帝國理工大學、香港理工大學、深圳大學、西南醫科大學等權威專家和教授組成，專注於放射性同位素和核醫藥的研究與臨床應用。 [caption id="attachment_2305" align="aligncenter" width="829"] （圖中從左往右依次為：磐美迪聯合技術委員會主席Robin Grimes院士，英國CEO Andrew Carlick院士, 中國CEO鄧立鳴先生以及董事局主席符展成先生）[/caption] Ac-225被認為是最具臨床應用前景的治療用醫用同位素之一，目前全球已有數十項Ac-225藥物管線進入臨床研究階段，覆蓋前列腺癌、神經內分泌腫瘤、非小細胞肺癌、乳腺癌以及多種實體瘤等適應症的多數癌種。 Ac-225在臨床研究和治療應用中因其優異的治療效果，不僅能提高患者的生存率，提高治療效果，減少治療副作用，而且有效降低醫療成本，已經成為全球各大藥企一致看好並爭相佈局的最優秀和最有前景的醫用同位素之一。而全球Ac-225的生產關鍵技術僅由國外極少數的幾個先進團隊掌握，生產工藝需要經過一系列複雜的核反應和分離過程，因此供應極其有限，產能資源長期嚴重稀缺。而隨著國內外相關臨床研究與治療需求的不斷增加，這種供需失衡進一步加劇了Ac-225的緊缺性。磐美迪彌補Ac-225的巨大供應缺口，倍受全球矚目，將有效地支持新癌症治療方法的進一步探索。該雙重價值，進一步體現了磐美迪作為全球健康事業的重要參與者之一，將致力以技術創新、國際合作推動全球健康為宗旨，堅定為實現人類命運共同體而努力的目標。磐美迪聯合創始人、英國董事CEO、Andrew Carlick院士表示：“磐美迪所採用迴旋加速器製備的Ac-225 技術十分成熟，已通過機構驗證，具有純度高、產量大、輻射低、原料損耗低等優勢。是我們多年來智慧和資源的結晶，在癌症治療方面發揮顯著作用，在國際化團隊共同的努力下，將繼續推動核醫藥技術的發展。” 磐美迪聯合創始人、中國董事CEO、鄧立鳴先生表示:“磐美迪將繼續致力於技術和工藝的創新發展，計畫未來進一步拓展如Ac-225和Ge-68等醫用同位素的應用領域，為放射性藥物的開發提供從原料到成品，從研究到放大以及商業化級別生產的全流程解決方案，構建從同位素生產、核心裝備研發、核藥RXO、新一代診斷設備到AI+TAT的核醫藥全流程技術體系平臺。在加強放射性藥物研發力量的同時，推進世界先進技術臨床轉化與應用，為科學研究和醫療健康貢獻磐美迪力量。” 磐美迪控股（深圳）有限公司公司聯絡人：Claire Zhao 公司聯繫方式：pchl@panmedisoholdings.com 公司官網：http://panmedisoholdings.com/

Kess Energy – Kess Energy Chairman Announces Purchase of 200,000 Shares

August 14, 2024

Brasilia, Brazil – August 14, 2024 – (SeaPRwire) – Kess Energy, a leading junior lithium mining company, is pleased to announce that its Chairman, Inato Ramirez, has purchased 200,000 shares of Kess Energy, further demonstrating his confidence in the company’s future growth and its commitment to delivering value to stakeholders. Strengthening Leadership Commitment The purchase of 200,000 shares by Mr. Ramirez serves to reiterate his strong belief in Kess Energy’s strategic direction and the significant potential of its lithium projects. This investment aligns the Chairman’s interests with those of the company’s stakeholders and signals robust confidence in Kess Energy’s long-term prospects. Chairman’s Statement “I am excited about the future of Kess Energy and our role in driving the global transition to sustainable energy,” said Mr. Ramirez. “This personal investment reflects my full confidence in our team, our assets, and our ability to execute our growth strategy. I am committed to ensuring that we continue to deliver exceptional value to our stakeholders.” Company Vision and Growth Strategy Kess Energy is at the forefront of the lithium industry, focusing on sustainable mining practices and innovation in the South American “lithium triangle”. The company’s strategic initiatives include expanding its lithium production capacity, advancing exploration projects, and forging partnerships to support the burgeoning demand for lithium in electric vehicles and renewable energy storage. About Kess Energy Kess Energy is a junior lithium mining company dedicated to meeting the increasing global demand for lithium through responsible and sustainable mining practices that respect and consider the needs of the communities in which its assets are located. With a portfolio of high-quality lithium assets and a commitment to innovation, Kess Energy is well-positioned to play a pivotal role in the energy transition while enabling communities to share in the commercial benefits of its business.. Forward-Looking Statements This press release contains forward-looking statements that involve risks and uncertainties. These statements are based on current expectations and projections about future events and are not guarantees of future performance. Actual results may differ materially from those expressed or implied in these statements due to various factors. Know more please contact Phone No.: +55 61 4042 9257, or visit our office at: Centro Empresarial Varig SCN QUADRA 04 BL B – Asa Norte, Brasília – DF, 70714-900, Brazil. Media Contact Brand: Kess Energy Contact: Joseph Hera Email: contact@kessenergy.com Website: https://kessenergy.com The article is provided by a third-party content provider. SeaPRwire ( https://www.seaprwire.com/ ) makes no warranties or representations in connection therewith. Sectors: Top Story, Corporate News SeaPRwire provides real time press release distribution for companies and organizations to 6,500+ media outlets & 3.5 million professional desktops in 90 regions. It distributes press releases in different languages, including: IndonesiaFolk, IndoNewswire, SEATribune, IDNewsZone, LiveBerita, DailyBerita, TaiwanPR, SinchewBusiness, AsiaEase, BuzzHongKong, SingapuraNow, TIHongKong, TaipeiCool, TWZip, AsiaFeatured, dePresseNow, THNewson, KULPR, VNFeatured, MENAEntry, HunaTimes, DubaiLite, ArabicDir, BeritaDaring, TekanAsia, JamKopi ...

SeaPRwire

Dr.Friend Puppy, Exhibits at Global Pet Show, Targeting Overseas Markets

August 14, 2024

Seoul, Korea – August 14, 2024 – (SeaPRwire) -The premium sleep and healthcare brand Dr.Friend’s pet sleep care product, Dr.Friend Puppy (owned by World Home Doctor Corp.), will be actively targeting overseas markets from the second half of the year. Dr.Friend Puppy will participate in the SUPER ZOO in Las Vegas, USA from August 14-16 to actively promote Dr.Friend’s unique sleep & healthcare technology. SUPER ZOO is one of the most established and prestigious pet industry trade shows in North America. It has been held since 1950, and it is considered the largest pet industry show in North America. It continues to be one of the most productive and vibrant shows yearly. Following CES2024 in January and IHS2024 in March, Dr.Friend Puppy will participate in Super Zoo to introduce its unique pet sleep care technology and pet humanization philosophy to pet industry stakeholders around the world. In particular, Dr.Friend Puppy is a pet-specific sleep care product that incorporates Dr.Friend’s sleep care technology, such as grounding technology and natural material technology. This has the advantage of harmonizing the natural characteristics of pets that are healthiest when they are in nature with the characteristics of their living environment. Dr.Friend’s core natural functional material technologies, such as charcoal wool with antibacterial properties and natural wool, are optimally proportioned to enhance pet sleep care without using chemicals such as memory foam, so pets can feel comfortable and stable sleeping environments every day. In addition, a water-repellent technology that coats a thin film on top of the fabric tissue is also applied to prevent contaminants that may occur due to the nature of the pet’s living environment from penetrating the surface of the fabric, making it more hygienic and convenient to use. By compensating for the disadvantage of sharing the same living environment as the owner, such as an apartment, pet grounding allows pets to get enough natural interaction in the comfort of their home. Dr.Friend will highlight various uniqueness and differentiation of Dr.Friend Puppy, such as realizing the value of pet humanization to ultimately maintain health, prevent various diseases, and reduce medical costs. “Dr.Friend’s grounding and natural material technology continues to gain scientific credibility through anti-inflammatory and stress relief studies that we have been conducting since 2018,” said Kim Ji Youn, CEO of Dr.Friend, who is participating in the exhibition. “In particular, the stress relief effect paper published in Biomedicines, an SCI-level journal, is showing high interest among animal healthcare professionals such as US veterinarians.” She also said, “As we are currently discussing clinical trials with domestic and foreign medical organizations to help improve pets’ health, we will actively promote the advantages of our sleep care technology and healthcare principles to expand cooperation opportunities with various buyers and partners.” After the Super Zoo exhibition, Dr.Friend Puppy will also participate in Pet Fair Asia, August 21-25 in Shanghai, China, expanding its growth strategy to the Asia Pacific region. Pet Fair Asia is Asia’s largest international pet products exhibition, and along with the Super Zoo, it is one of the world’s largest and most influential pet shows. This year’s event will be the largest since its inception in 1997, and Dr.Friend will present its authentic sleep &healthcare value and technology to more than 100,000 buyers and visitors, exploring opportunities to expand sales and establish strategic partnerships. About Dr. Friend Dr. Friend is a sleep care functional bedding brand that combines ergonomic functions and premium materials. It was created through continuous research and development for a long period of time to realize a safe and stable sleeping environment and to satisfy customers at all times. Media Contact Brand: Dr.Friend Puppy (World Home Doctor Corp.) Contact : Chon GyeongUn Email: cgu0823@worldhomedr.com Phone: +8210-4981-6360 Website: https://worldhome.global/ The article is provided by a third-party content provider. SeaPRwire ( https://www.seaprwire.com/ ) makes no warranties or representations in connection therewith. Sectors: Top Story, Corporate News SeaPRwire provides real time press release distribution for companies and organizations to 6,500+ media outlets & 3.5 million professional desktops in 90 regions. It distributes press releases in different languages, including: IndonesiaFolk, IndoNewswire, SEATribune, IDNewsZone, LiveBerita, DailyBerita, TaiwanPR, SinchewBusiness, AsiaEase, BuzzHongKong, SingapuraNow, TIHongKong, TaipeiCool, TWZip, AsiaFeatured, dePresseNow, THNewson, KULPR, VNFeatured, MENAEntry, HunaTimes, DubaiLite, ArabicDir, BeritaDaring, TekanAsia, JamKopi ...

SeaPRwire

C14 Enters into Partnership with Tune.FM

August 14, 2024

New York, NY – August 14, 2024 – (SeaPRwire) – C14, a leading provider of fiat-to-crypto on and off-ramp solutions, has joined forces with Tune.FM, a cutting-edge music NFT trading platform, to release an off-ramp solution for JAM, the native token of the Tune.fm application. This collaboration marks a significant step forward in the integration of cryptocurrency with the music industry, providing users with seamless conversion of JAM tokens to fiat currency. Tune.fm is a revolutionary platform where artists and fans can trade music NFTs, unlocking new revenue streams and interactive experiences in the music ecosystem. The native token, JAM, is at the heart of Tune.fm’s economy, facilitating transactions and rewarding artists and fans alike. With the introduction of an off-ramp solution, users will now have the ability to convert JAM tokens into fiat currency, enhancing the platform’s usability and accessibility. This partnership deepens C14 and Tune.fm’s existing relationship, where C14 provides on-ramping services for Tune.fm’s existing base of over TK users. C14 provides ramping services for JAM for users in over two dozen countries. JAM is built on the Hedera Hashgraph, a low cost, high throughput distributed ledger technology. C14 has established itself as a trusted partner in the crypto space, offering robust solutions that bridge the traditional financial system with the digital asset world. The off-ramp for JAM tokens leverages C14’s secure and efficient infrastructure, ensuring a smooth and reliable conversion process. C14 and Tune.FM will roll out service for users in the United States versus ACH first, with instant SEPA payouts to the European Union following soon after. Key Benefits of the Collaboration Seamless Conversion: Users can easily convert their JAM tokens into fiat currency, broadening the utility and acceptance of JAM in the real world. Enhanced Accessibility: The off-ramp solution lowers the barriers for new users to engage with Tune.FM, providing a straightforward method to cash out their JAM tokens. Security and Trust: C14’s proven track record in the industry ensures a safe and compliant process for all transactions, instilling confidence in users. “Partnering with Tune.fm aligns perfectly with our mission to make crypto accessible to everyone,” said Erich Grant, CEO of C14. “We are excited to support the vibrant community of artists and fans on Tune.fm by providing an easy and secure way to convert JAM tokens to fiat currency.” “This collaboration with C14 is a game-changer for our platform,” added Andrew Antar, CEO of Tune.FM. “The off-ramp solution not only enhances the user experience but also paves the way for wider adoption of JAM tokens in the mainstream economy.” The off-ramp for JAM tokens is expected to be available to Tune.FM users starting July 25th For more information on how to use the off-ramp, visit Tune.FM. About C14 C14 is a leading provider of fiat-to-crypto on and off-ramp solutions, dedicated to bridging the gap between traditional finance and the digital asset economy. With a focus on security, compliance, and user experience, C14 offers seamless conversion services that empower users to interact with the crypto world effortlessly. To know more please contact +1 (845) 366-6902. About Tune.FM Tune.fm is a pioneering music NFT trading platform that empowers artists and fans to engage in a vibrant digital music economy. By leveraging blockchain technology and the JAM token, Tune.FM enables transparent and rewarding interactions within the music industry, fostering a new era of music ownership and distribution. Media Contacts Erich Grant, Founder of C14 erich@c14.money Website: https://c14.money/ Andrew Antar, Founder of Tune.FM hello@Tune.FM Website: http://tune.fm/ The article is provided by a third-party content provider. SeaPRwire ( https://www.seaprwire.com/ ) makes no warranties or representations in connection therewith. Sectors: Top Story, Corporate News SeaPRwire provides real time press release distribution for companies and organizations to 6,500+ media outlets & 3.5 million professional desktops in 90 regions. It distributes press releases in different languages, including: IndonesiaFolk, IndoNewswire, SEATribune, IDNewsZone, LiveBerita, DailyBerita, TaiwanPR, SinchewBusiness, AsiaEase, BuzzHongKong, SingapuraNow, TIHongKong, TaipeiCool, TWZip, AsiaFeatured, dePresseNow, THNewson, KULPR, VNFeatured, MENAEntry, HunaTimes, DubaiLite, ArabicDir, BeritaDaring, TekanAsia, JamKopi ...

1 …23 24 25